Majewski S, Skopinska-Rozewska E, Jablonska S, Polakowski I, Pawinska M, Marczak M, Szmurlo A
Arthritis Rheum. 1985 Oct;28(10):1133-9. doi: 10.1002/art.1780281009.
Sera from 22 patients with progressive systemic sclerosis were tested for the ability to modify the angiogenic capability of normal human mononuclear cells. The sera from patients with acrosclerosis, including the abortive form (CREST syndrome: calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), markedly enhanced this capability compared with sera from both healthy donors and patients with severe acrosclerosis and diffuse scleroderma. The enhancing effect of sera from patients with acrosclerosis decreased and/or disappeared in cases where the patient's acrosclerosis was chronic and severe. Thus, this test may be of diagnostic value in distinguishing various subgroups of systemic sclerosis.
对22例进行性系统性硬化症患者的血清进行检测，以评估其改变正常人单核细胞血管生成能力的作用。肢端硬化症患者的血清，包括顿挫型（CREST综合征：钙质沉着、雷诺现象、食管运动障碍、指（趾）硬皮病、毛细血管扩张），与健康供者以及重症肢端硬化症和弥漫性硬皮病患者的血清相比，显著增强了这种能力。在肢端硬化症患者为慢性重症的情况下，其血清的增强作用减弱和/或消失。因此，该检测对于区分系统性硬化症的不同亚组可能具有诊断价值。
